Selank

No — selank produces anxiolysis by potentiating GABA-A receptor activity (an indirect benzodiazepine-like effect at the receptor level) but does not bind the benzodiazepine allosteric site directly. The result is anxiolytic effects without the sedation, memory impairment, or dependency/tolerance profile of benzodiazepines. It is a mechanistically distinct anxiolytic.

Selank has been suggested as a support tool during benzodiazepine tapering due to its GABAergic properties. However, benzodiazepine discontinuation is a medical process and should be managed by a physician. Selank may reduce anxiety symptoms during the taper but is not a formal medical treatment for benzodiazepine withdrawal syndrome.

Intranasal selank typically produces noticeable anxiety reduction within 15-30 minutes via the olfactory-CNS pathway. This rapid onset makes it suitable for acute situational use (before presentations, social events, high-stress work blocks) as well as regular daily dosing.

Yes, unlike benzodiazepines, selank does not develop tolerance with consistent use. Clinical studies of up to 4 weeks show no evidence of tolerance or dependency. Cycling is still commonly recommended (3 weeks on, 1 week off) as a conservative practice, though it may not be strictly necessary.

At standard doses (250-500 mcg), selank does not produce sedation in most users. The anxiolytic effect is accompanied by improved cognitive clarity rather than impairment — distinguishing it from virtually all pharmaceutical anxiolytics. At very high doses, mild drowsiness has been occasionally reported.

Yes — social anxiety (performance in social situations) is one of the applications most commonly reported by users. The combination of anxiolytic effect, improved verbal fluency from BDNF/dopaminergic modulation, and absence of sedation makes it particularly well suited to social performance contexts.